[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394-424.
[2] HUANG H, PAN X, JIN H, et al.PHLPP2 downregulation contributes to lung carcinogenesis following B[a]P/B[a]PDE exposure[J]. Clinical Cancer Research, 2015, 21(16): 3783-3793.
[3] HOFFMANN D, HOFFMANN I, EL-BAYOUMY K.The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder[J]. Chemical Research in Toxicology, 2001, 14(7): 767-790.
[4] HECHT S S.Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines[J]. Chemical Research in Toxicology, 1998, 11(6): 559-603.
[5] WAKAMATSU N, DEVEREUX T R, HONG H H L, et al. Overview of the molecular carcinogenesis of mouse lung tumor models of human lung cancer[J]. Toxicologic Pathology, 2007, 35(1): 75-80.
[6] HECHT S S, KASSIE F, HATSUKAMI D K.Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers[J]. Nature Reviews Cancer, 2009, 9(7): 476-488.
[7] HANAHAN D, WEINBERG R A.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
[8] BHAT T A, PANZICA L, KALATHIL S G, et al. Immune dysfunction in patients with chronic obstructive pulmonary disease[J]. Annals of the American Thoracic Society, 2015, 12 Suppl 2(3): 169-175.
[9] MEIROW Y, BANIYASH M.Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases[J]. Cancer Immunology, Immunotherapy, 2017, 66(8): 1089-1101.
[10] LU J Y, ZHANG M, HUANG Z Y, et al.SIRT1 in B[a]P-induced lung tumorigenesis[J]. Oncotarget, 2015, 6(29): 27113-27129.
[11] ALTORKI N K, MARKOWITZ G J, GAO D C, et al.The lung microenvironment: an important regulator of tumour growth and metastasis[J]. Nature Reviews Cancer, 2019, 19(1): 9-31.
[12] ROCHE P A, FURUTA K.The ins and outs of MHC class II-mediated antigen processing and presentation[J]. Nature Reviews Immunology, 2015, 15(4): 203-216.
[13] INABA K, TURLEY S, IYODA T, et al.The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli[J]. The Journal of Experimental Medicine, 2000, 191(6): 927-936.
[14] BALKWILL F.Tumour necrosis factor and cancer[J]. Nature Reviews Cancer, 2009, 9(5): 361-371.
[15] APOSTOLAKI M, ARMAKA M, VICTORATOS P, et al.Cellular mechanisms of TNF function in models of inflammation and autoimmunity[M]//Current Directions in Autoimmunity. Basel: KARGER, 2010: 1-26.
[16] JUREWICZ M M, STERN L J.Class II MHC antigen processing in immune tolerance and inflammation[J]. Immunogenetics, 2019, 71(3): 171-187.
[17] KOPPELMAN B, NEEFJES J J, DE VRIES J E, et al. Interleukin-10 down-regulates MHC class II αβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling[J]. Immunity, 1997, 7(6): 861-871. |
